ABSTRACT: Most patients with autoimmune diseases are thought to have a a normal life expectancy, and thus are treated conservatively. However, these diseases have a diverse clinical course. A small subset of patients have "severe autoimmune diseases," or SADS, which are rapidly progressive and are associated with early mortality. If patients with SADS can be identified before they develop irreversible organ damage, aggressive intervention would be indicated. Consequently, patients with SADS are now being enrolled in experimental protocols of immune ablation and hematopoietic stem-cell rescue (ie, bone marrow transplantation [BMT]) at several US institutions. For various reasons, including the high cost of BMT, it will probably be years before the benefits, if any, of this procedure are known. [ONCOLOGY 11(7):1001-1017, 1997]
There are numerous autoimmune diseases that, depending on the predominant organ system involved, are treated by a variety of medical subspecialists. The common philosophy in the treatment of all these disorders is suppression or modulation of the immune system in an attempt to ameliorate pain, disability, or organ dysfunction. Many autoimmune diseases are viewed as having a good prognosis and are treated conservatively. Overall survival for most afflicted individuals is generally accepted as normal, although impairment of vocational or avocational activities may occur.
Another general feature of autoimmune diseases, however, is their diverse clinical course. This may range from a single episode without residual damage, to an indolently progressive disease with significant disability to a rapidly progressive disease with early mortality (in a small subset of patients). It is this latter subset of patients with a high risk of early mortality for whom Alberto Marmont coined the term "severe autoimmune diseases" (SADS).[A. Marmont, Genova, Italy, personal communication] If patients with SADS can be identified before they develop irreversible organ damage, aggressive intervention would be indicated. For this reason, patients with SADS are now being enrolled in experimental protocols of immune ablation and hematopoietic stem-cell rescue at several institutions in the United States (Table 1).
The first successful human allogeneic bone marrow transplants were performed in children with immune deficiencies (severe combined immunodeficiency and Wiskott-Aldrich syndrome). A normal immune system was generated in these children following transplantation of marrow from their unaffected siblings.
The rationale for the use of BMT in SADS is to condition the patient with a chemoradiotherapeutic regimen to ablate the immune and hematopoietic compartments and then rescue the patient from fatal aplasia by reinfusing hematopoietic progenitor cells. The infused stem cells will give rise to new differentiated cells of hematopoietic lineage, including red blood cells, platelets, neutrophils, and immune cells, such as B- and T-lymphocytes, natural killer cells, monocytes, and tissue macrophages.
The concept that BMT can cure autoimmune disease has already been demonstrated in aplastic anemia. In most cases, aplastic anemia arises from immune suppression of hematopoiesis. Depending on a patient's age and the availability of an HLA-matched sibling, initial treatment is either immunosuppression (eg, cyclosporine [Sandimmune] and antithymocyte globulin) or allogeneic BMT. Therefore, the standard of care for one human autoimmune disease, aplastic anemia, is already allogeneic BMT.
Ideally, specific immunosuppression could be targeted to regulate an autoreactive subset of lymphocytes while leaving the overall immune system intact. However, animal studies suggest that once inflammation is initiated against an immunodominant epitope, T-cell clones are recruited against other intramolecular and intermolecular subdominant or cryptic epitopes in the target tissue. This phenomenon of epitope-spreading would argue against any long-lasting effectiveness of specific immunotherapy and in favor of nonspecific immune ablation. Currently, corticosteroids, cyclophosphamide (Cytoxan, Neosar), and azathioprine are examples of broad-spectrum immunosuppressive agents used to treat autoimmune diseases.
Bone marrow transplantation maximizes the dose intensity of immunosuppression to the point of complete immune ablation. In addition, for more than 1 year following either autologous or allogeneic hematopoietic stem-cell reconstitution, the immune system is functionally immunosuppressed. The CD4 count is depressed, and the CD4/CD8 ratio is inverted for 12 to 18 months despite an otherwise healthy graft.[3,4]
Theoretically, BMT may induce lasting remission of an autoimmune disease by: (1) regeneration of a naive immune system, which may remain unresponsive to "self" until reexposure to the original disease-initiating agent(s); (2) generation or infusion of suppressor cells; (3) infusion of genetically distinct allogeneic stem cells, giving rise to T-cells and antigen-presenting cells with different major and/or minor histocompatibility complex surface molecules; and (4) generation of tolerance through exposure of lymphocyte precursors to self-epitopes early in development, possibly resulting in anergy and/or deletion of autoreactive repertoires.
If most autoimmune diseases were inherited as hematopoietic stem-cell defects, rescue with autologous hematopoietic stem cells would not be expected to cure the disease. However, most human autoimmune diseases do not appear to be an environmentally independent defect in hematopoietic stem cells since the majority of monozygotic twins are discordant for clinical disease. Although HLA association with certain autoimmune diseases suggests a genetic predisposition, environmental factors are probably required to initiate these diseases. Even if genetics did play a significant role in some autoimmune disorders, allogeneic stem-cell rescue from an HLA-matched but unaffected sibling might still prevent the disease.
There are two broad categories of autoimmune diseases in animals: those that arise spontaneously and those that require immunization. In general, spontaneously occurring autoimmune diseases are restricted to inbred strains and arise from genetic defects in the hematopoietic stem-cell compartment. On the other hand, diseases that arise after immunization may occur in a variety of outbred species and are due to priming (ie, activation) of normal, previously naive (ie, unresponsive) lymphocytes. The lymphocytic repertoire of animals that develop disease after immunization is obviously capable of recognizing self-antigens. What is not obvious is how these lymphocytes remain unresponsive until immunized to the self-protein.
Spontaneously Occurring Diseases
Examples of spontaneously occurring autoimmune diseases include: a systemic lupus erythematosus (SLE)-like syndrome in Murphy Roth Lab lymphoproliferative (MRL/lpr mice and in the offspring between New Zealand black/New Zealand white mice (NZB/NZW F1 hybrid [B/W])[5-7]; a scleroderma-like illness in Tight-skin (Tsk) mice[8,9] and University of California Davis Line 200 (UCD) L200 chickens[10,11]; an inflammatory bowel disease in cotton top tamarin monkeys; and an islet-cell inflammatory disease similar to type I diabetes mellitus in nonobese diabetic (NOD) mice[13,14] (Table 2). With the exception of the MRL/lpr mouse, the exact genetic defect(s) remain(s) enigmatic.
The MRL/lpr strain of mice develops a massive lymphoproliferative disease characterized by arthritis, glomerulonephritis, vasculitis, and anti-double-stranded (anti-ds) DNA antibody. These mice have a single gene defect that prevents high level expression of Fas, a protein that signals for apoptosis.[15,16] Normal mice express high levels of the Fas protein on CD4/CD8 double-positive thymocytes, inducing apoptosis of potentially autoreactive T-cell clones. T-cells normally upregulate Fas-surface protein when activated, which serves to control a lymphoproliferative response by inducing cell death. In MRL/lpr mice, autoimmunity results from a lack of normal lymphocyte programmed cell death. Transplantation of hematopoietic stem cells from MRL/lpr mice into an unaffected strain of mice results in the MRL/lpr phenotype and early death.
The NZB mouse develops spontaneous hemolytic anemia and a high titer of antierythrocyte antibodies.[5,6] When bred with the phenotypically normal NZW mouse, the offspring (F1 hybrid, B/W) develop a fatal immune glomerulonephritis and a high titer of anti-ds DNA antibody. Although hemolysis may occur, it is not prominent. The genetic defect in B/W mice is unknown, but transplantation of lymphocyte-depleted marrow into a normal mouse from another strain causes fatal immune glomerulonephritis. Similarly, transplantation of lymphocyte-depleted marrow from Tsk or NOD mice into a genetically nonsusceptible strain results in a scleroderma-like illness and diabetes, respectively.
Animal autoimmune diseases that arise after immunization with the appropriate self-epitope include: adjuvant-induced arthritis, collagen-induced arthritis,[19,20] experimental autoimmune myasthenia gravis,[21,22] experimental autoimmune encephalomyelitis,[23,24] and experimental autoimmune myositis. In all of these diseases, injection of tissue-specific protein in complete Freund's adjuvant initiates disease in susceptible species. The experimental autoimmune encephalomyelitis model will be presented as an example of an autoimmune disease that arises by immunization with target organ homogenate or immunodominant peptide(s).
Experimental autoimmune encephalomyelitis was first discovered as a disease in humans following immunization with the Pasteur vaccine for prevention of rabies. Patients developed an ascending paralysis due to contamination of the vaccine by rabbit central nervous system antigens. Subsequently, it was found that injection of spinal cord homogenate with Freund's adjuvant causes neurologic deficits in a wide variety of species, including mice, rats, rabbits, guinea pigs, and monkeys.
Disease manifestations vary by species. Lewis rats develop a monophasic ascending paralysis with a transient inflammatory spinal cord infiltrate. In the Buffalo rat, experimental autoimmune encephalomyelitis presents as an acute hemorrhagic encephalomyelitis. In the SJL/J mouse, experimental autoimmune encephalomyelitis manifests as an inflammatory, demyelinating, relapsing/remitting disease similar to relapsing/remitting multiple sclerosis (MS).
Further studies have shown that small amino acid sequences of myelin can also initiate experimental autoimmune encephalomyelitis. Several proteins are present in myelin, including proteolipid protein and myelin basic protein. Proteolipid protein is specific to the central nervous system, whereas myelin basic protein is present in both the central and peripheral nervous systems. Immunogenic myelin peptide sequences include proteolipid protein peptide sequence 139-151 or 178-191 and myelin basic protein peptide sequence 84-102. If the animal is immunized with only proteolipid protein sequence 139-151, peripheral lymphocytes during the first relapse proliferate only to proteolipid protein sequence 139-151. During subsequent relapses, epitope-spreading occurs, with lymphocytes proliferating to proteolipid protein sequences 139-151 and 178-191, as well as peptide sequences from other myelin proteins, such as myelin basic protein sequence 84-102.
Use of BMT in Animal Models
Immune ablation and hematopoietic rescue has been attempted in several animal autoimmune disorders (Table 2). Diseases that arise spontaneously and are thought to be secondary to a stem-cell defect have been cured by allogeneic BMT from a strain resistant to the disease. For example, diabetes in the NOD mouse may be prevented by a hematopoietic stem-cell transplant from a nonsusceptible strain. Immune glomerulonephritis, anti-ds DNA antibody, and lymphocytic infiltration of the liver and kidneys disappear in lupus-prone mice after allogeneic transplantation from a nonsusceptible strain.[27-29]
In contrast to stem cell-mediated autoimmunity, animal models of autoimmune disease induced by immunization have been arrested by either allogeneic, syngeneic, or autologous BMT (Table 2). Following autologous BMT, the inflammatory synovitis of adjuvant-induced arthritis resolves.[30,31] After syngeneic BMT in animals with experimental autoimmune myasthenia gravis, anti-acetylcholine receptor antibodies disappear and weakness reverses, while in experimental auto- immune encephalomyelitis, neurologic progression is stopped.[33-36]
Syngeneic BMT from an unimmunized animal, if done before disease onset, prevents experimental autoimmune encephalomyelitis. If performed after the onset of neurologic disease, syngeneic BMT prevents clinical progression and peripheral lymphocytes no longer proliferate to myelin epitopes. Although the immunologic attack may be arrested, remyelination and/or axonal repair is necessary to reverse established neurologic damage. Therefore, depending on the animal and stage of disease, neurologic deficits may not completely resolve.
The results of BMT in animal autoimmune disorders suggest that diseases arising from a stem-cell defect require an allogeneic donor from an unaffected strain to be cured. In contrast, autoimmune diseases that arise from environmental stimuli (ie, immunization) may be cured by a syngeneic or an autologous graft. The role of purging lymphocytes from an autologous graft has not yet been addressed in animal models. Finally, the results of BMT in experimental autoimmune encephalomyelitis suggest that cure of an autoimmune disease may not ultimately benefit the patient since repair of the affected target organ may not occur.
1. Gatti RA, Meuwissen HJ, Allen HD, et al: Immunological reconstitution
of sex-linked lymphopenic immunological deficiency. Lancet 1:1366-1369,
2. McRae BL, Vanderlugt CL, Dal Canto MC, et al: Functional evidence
for epitope spreading in the relapsing pathology of experimental autoimmune
encephalomyelitis. J Exp Med 182:75-86, 1995.
3. Forman SJ, Nocker P, Gallagher M: Pattern of T cell reconstitution
following allogeneic bone marrow transplantation for acute hematologic
malignancy. Transplantation 34:96-98, 1982.
4. Olsen GA, Gockerman JP, Bast RC, et al: Altered immunologic reconstitution
after standard dose chemotherapy or high dose chemotherapy with autologous
bone marrow support. Transplantation 46:57-60, 1988.
5. Heyler BJ, Howie JB: Renal disease associated with positive lupus
erythematosus tests in a cross bred strain of mice. Nature 197:197, 1963.
6. Putterman C, Naparstek Y: Murine models of spontaneous systemic lupus
erythematosus, in Autoimmune Disease Models: A guidebook, pp 217-243. San
Diego, Academic Press, Inc., 1994.
7. Akizuki M, Reeves JP, Steinberk AD: Expression of autoimmunity by
NZB/NZW marrow. Clin Immunol Immunopathol 10:247-250, 1978.
8. Jimenez SD, Christner P: Animal models of systemic sclerosis. Clin
Dermatol 12:425-436, 1994.
9. Kasturi KN, Shibata S, Muryoi T, et al: Tight-skin mouse: An experimental
model for scleroderma. Int Rev Immunol 11:253-271, 1994.
10. van de Water J, Boyd R, Wick G, et al: The immunologic and genetic
basis of avian scleroderma, an inherited fibrotic disease of line 200 chickens.
Int Rev Immunol 11:273-282, 1994.
11. Rose NR: Avian models of autoimmune disease: Lessons from the birds.
Poul Science 73:984-990, 1994.
12. Warren BF, Watkins PE: Animal models of inflammatory bowel disease.
J Pathol 172:313-316, 1994.
13. Mendez JD, Ramos HG: Animal models in diabetes research. Arch Med
Res 25(4):367-375, 1994.
14. Hanafusa T, Miyagawa J, Nakajima H, et al: The NOD mouse. Diabetes
Res Clin Pract 24(suppl):S307-S311, 1994.
15. Cohen PL, Eisenberg RA: The lpr and gld genes in systemic autoimmunity:
Life and death in the Fas lane. Immunol Today 13(11):427-428, 1992.
16. Drappa J, Brot N, Elkon KB: The Fas protein is expressed at high
levels on double positive thymocytes and activated mature T cells in normal
but not MRL/lpr mice. Proc Natl Acad Sci USA 90:10340-10344, 1993.
17. Walker MA, Harley RA, Delustro FA, et al: Adoptive transfer of tight-skin
fibrosis to +/+ recipients by tsk bone barrow and spleen cells. Proc Soc
Exp Biol Med 192:196-200, 1989.
18. LaFace DM, Peck AB: Reciprocal allogeneic bone marrow transplantation
between NOD mice and diabetes-nonsusceptible mice associated with transfer
and prevention of autoimmune diabetes. Diabetes 38:894-901, 1989.
19. Hayashida K, Ochi T, Fujimoto M, et al: Bone marrow changes in adjuvant-induced
and collagen-induced arthritis. Arthritis Rheum 35(2):241-245, 1992.
20. Durie FH, Fava RA, Noelle RJ: Collagen-induced arthritis as a model
of rheumatoid arthritis. Clin Immunol Immunopathol 73(1):11-18, 1994.
21. Patrick J, Lindstrom J: Autoimmune response to acetylcholine receptor.
Science 180:871-872, 1973.
22. Vincent A: Experimental autoimmune myasthenia gravis, in Autoimmune
Disease Models: A Guidebook, pp 83-106. San Diego, Academic Press, 1994.
23. Brocke S, Gijbels K, Steinman L: Experimental autoimmune encephalomyelitis
in the mouse, in Autoimmune Disease Models: A Guidebook, pp 1-14. San Diego,
Academic Press, Inc., 1994.
24. Steinman L, Schwartz G, Waldor M, et al, in EAE: A Good Model for
MS, pp 393-397. San Diego, Academic Press, Inc., 1984.
25. Rosenberg N: Experimental models of inflammatory myopathies. Bailliere's
Clinical Neurology 2(3) 693-703, 1993.
26. Remlinger J: Accidents paralytiques au cours du traitment antirabique.
Ann Inst Pasteur 19:625-646, 1905.
27. Ikehara S, Good RA, Nakamura T, et al: Rationale for bone marrow
transplantation in the treatment of autoimmune diseases. Proc Natl Acad
Sci USA 82:2483-2487, 1985.
28. Himeno K, Good RA: Marrow transplantation from tolerant donors to
treat and prevent autoimmune diseases in BXSB mice. Proc Natl Acad Sci
USA 85(7):2235-2239, 1988.
29. Ikehara S, Yasumizu R, Inaba M, et al: Long-term observations of
autoimmune-prone mice treated for autoimmune disease by allogeneic bone
marrow transplantation. Proc Natl Acad Sci USA 86:3306-3310, 1989.
30. Kamiya M, Sohen S, Yamane T, et al: Effective treatment of mice
with type II collagen induced arthritis with lethal radiation and bone
marrow transplantation. J Rheumatol 20:225-230, 1993.
31. Knaan-Schanzer S, Houben P, Kinwel-Bohre EP, et al: Remission induction
of adjuvant arthritis in rats by total body irradiation and autologous
bone marrow transplantation. Bone Marrow Transplant 8:333-338, 1991.
32. Pestronk A, Drachman DB, Teoh R, et al: Combined short-term immunotherapy
cures experimental autoimmune myasthenia gravis. Ann Neurol 14:235-241,
33. Karussis DM, Vaurka-Karussis U, Lehmann D, et al: Prevention and
reversal of adoptively transferred, chronic relapsing experimental autoimmune
encephalomyelitis with a single high dose cytoreductive treatment followed
by syngeneic bone marrow transplantation. J Clin Invest 765-772, 1993.
34. van Gelder M, Kinwel-Bohre EPM, van Bekkum DW: Treatment of experimental
allergic encephalomyelitis in rats with total body ir- radiation and syngeneic
BMT. Bone Marrow Transplant 11:233-241, 1993.
35. van Gelder M, van Bekkum DW: Treatment of relapsing experimental
autoimmune encephalomyelitis in rats with allogeneic bone marrow transplantation
from a resistant strain. Bone Marrow Transplant 16:343-351, 1995.
36. Burt RK, Hess A, Burns W, et al: Syngeneic bone marrow transplantation
eliminates vb8.2T lymphocytes from the spinal cord of Lewis rats with experimental
allergic encephalomyelitis. J Neuroscience Res 41:526-531, 1995.
37. Lowenthal RM, Cohen ML, Atkinson K, et al: Apparent cure of rheumatoid
arthritis by bone marrow transplatation. J Rheumatol 20(1):137-140, 1993.
38. McKendry RJR, Huebsch L, Leclair B: Progression of rheumatoid arthritis
following bone marrow transplantation: A case report with 13 year followup.
Arthritis Rheum 39:1246-1253, 1996.
39. Liu Yin JA, Jowitt SN: Resolution of immune-mediated diseases following
allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant
40. McAllister LD, Beatty PG, Rose J: Allogeneic bone marrow transplantation
for chronic myelogenious leukemia in a patient with multiple sclerosis:
case study. Bone Marrow Transplant, 1997 (in press).
41. Salzman P, Tami J, Jackson C, et al: Clinical remission of myasthenia
gravis after high dose chemotherapy and autologous transplantation with
CD34+ stem cells (abstract). Blood 84(10; suppl 1):206a, 1994.
42. Fastenrath S, Dreger P, Schmitz N: Autologous unpurged bone marrow
transplantation in a patient with lymphoma and SLE: Short-term recurrence
of antinuclear antibodies. Arthritis Rheum 38(9):S303, 1995.
43. Euler HH, Marmont AM, Bacigalupo A, et al: Early recurrence or persistence
of autoimmune diseases after unmanipulated autologous stem cell transplantation.
Blood 88(9):3621-3625, 1996.
44. Weinshenker BG: The natural history of multiple sclerosis. Multiple
Sclerosis 13(1)119-146, 1995.
45. McFarland HG: Editorial: Twin studies and multiple sclerosis. Ann
Neurol 32:722, 1992.
46. Kurtzke JF, Hyllested K, Heltberg A, et al: Multiple sclerosis in
the Faroe Islands. Acta Neurol Scand 88:161-173, 1993.
47. Kurtzke JF: Rating neurologic impairment in multiple sclerosis:
An expanded disability status scale (EDSS). Neurology (Cleveland) 33:1444-1452,
48. Sipe JC, Knobler RL, Braheny SL, et al: A neurologic rating scale
(NRS) for use in multiple sclerosis. Neurology (Cleveland) 34:1368-1372,
49. Miller DH: Magnetic resonance in monitoring the treatment of multiple
sclerosis. Ann Neurol 36(suppl):S91-S94, 1994.
50. Frank JA, Stone LA, Smith ME, et al: Serial contrast-enhaced magnetic
resonance imaging in patients with early relapsing-remitting multiple sclerosis:
implications for treatment trials. Ann Neurol 36(suppl):S86-S90, 1994.
51. Francis GS, Evans AC, Aronold DL: Neuroimaging in multiple sclerosis.
Multiple Sclerosis 13(1):147-17, 1995.
52. Pincus T, Brooks RH, Callahan LF: Prediction of long-term morality
in patients with rheumatoid arthritis according to simple questionaire
and joint count measures. Ann Intern Med 120:26-34, 1994.
53. Pincus T, Callahan LF: Rheumatology function tests: Grip strength,
walking time, button test and questionnaires document and predict long-term
morbidity and morality in rheumatiod arthritis. J Rheum 19(7):1051-1057,
54. Pincus T: Rheumatoid arthritis: A medical emergency? Scand J Rheum
23(suppl 100):21-30, 1994.
55. Jacobsson LT, Knowler WC, Pillemer S, et al: A cross-sectional and
longitudinal comparison of the Rome criteria for active rheumatoid arthritis
(equivalent to the American College of Rheumatology 1958 criteria) and
the American College of Rheumatology 1987 criteria for rheumatoid arthritis.
Arthritis Rheum 37(10):1479-1486, 1994.
56. Furst DE: Predictors of worsening clinical variables and outcomes
in rheumatoid arthritis. Diagnostic Issues 20(2):309-319, 1994.
57. Corbett M, Dalton S, Young A, et al: Factors predicting death, survival
and functional outcome in a prospective study of early rheumatoid disease
over fifteen years. Br J Rheum 32:717-723, 1993.
58. Wolfe F, Mitchell DM, Sibley JT, et al: The morality of rheumatoid
arthritis. Arthritis Rheum 37(4):481-494, 1994.
59. Myllykangas-Luosujarvi R, Aho K, Kautiainen H, et al: Shortening
of life span and causes of excess morality in a population-based series
of subjects with rheumatoid arthritis. Clin Exp Rheum 13:149-153, 1995.
60. Bendtsen P, Bjurulf P, Trell E, et al: Cross-sectional assessment
and subgroup comparison of functional disability in patients with rheumatoid
arthritis in a Swedish health-care district. Disabil Rehabil 17(2):94-99,
61. Pincus T, Callahan LF: The "side effects" of rheumatoid
arthritis: Joint destruction, disability and early mortality. Br J Rheumatol
32(suppl 1):28-37, 1993.
62. Pincus T, Summey JA, Soraci SA Jr., et al: Assessment of patient
satisfaction in activities of daily living using a modified Stanford Health
Assessment Questionnaire. Arthritis Rheum 26(11):1346-1353, 1983.
63. Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for
the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271-1277,
64. Cheigh JS, Kim H, Stenzel KH, et al: Systemic lupus erythematosus
in patients with end-stage renal disease: Long term follow-up on the prognosis
of patients and the evolution of lupus activity. Am J Kidney Dis 16(3):189-195,
65. Seleznick MJ, Fries JF: Variables associated with decreased survival
in Systemic lupus erythematosus. Semin Arthritis Rheum 21(2):73-80, 1991.
66. Gladman DD: Prognosis of systemic lupus erthematousus and factors
that affect it. Rheumatology 4:681-687, 1992.
67. Choen MG, Li EK: Morality in systemic lupus erythematosus: Active
disease is the most important factor. NZ J Med 22:5-8, 1992.
68. Churg J, Sobin LN: Glomerular diseases, in Renal Disease Classification
and Atlas, vol 1. Tokyo, Igaku-shoin, 1982.
69. Kashgarian M: New approaches to clinical pathologic correlation
in lupus nephritis. Am J Kidney Dis 2:164-169, 1982.
70. Austin, HA III, Muenz LR, Joyce KM, et al: Prognostic factors in
lupus nephritis: Contribution of renal histology data. Am J Med 75:382-391,
71. McLaughlin J, Gladman DD, Urowitz MB, et al: Kidney biopsy in systemic
lupus erythematosus. Arthritis Rheum 34(10):1268-1272, 1991.
72. Bombardier C, Gladman DD, Urowitz MB, et al: Derivation of the SLEDAI:
A disease activity index for lupus patients. Arthritis Rheum 35(6):630-640,
73. Abu-Shakra M, Urowitz MB, Gladman DD, et al: Morality studies in
systeic lupus erythematosus, results from a single center: II. Predictor
variables for mortality. J Rheum 22(7):1265-1270, 1995.
74. Cohen MG, Li EK: Morality in systemic lupus erythematosus: Active
disease is the most important factor. Aust NZ J Med 22:5-8, 1992.
75. Gladman DD: Indicators of disease activity, prognosis, and treatment
of systemic lupus erythematosus. Curr Opin Rheumatol 5:587-595, 1993.
76. Gulko PS, Reveille JD, Koopman WJ, et al: Anticardiolipin antibodies
in systemic lupus erythematosus: Clinical correlates, HLA associations,
and impact on survival. J Rheum 20(10):1684-1693, 1993.
77. Drenkard C, Villa AR, Alarcon-Segovia D, et al: Influence of the
antiphospholipid syndrome in the survival of patients with systemic lupus
erythematosus. J Rheum 21(6):1067-1072, 1994.
78. Alarcon-Segovia D, Deleze M, Oria CV, et al: Antiphospholipid antibodies
and the antiphospholipid syndrome in systemic lupus erythematosus. Medicine
79. Jouhikainen T, Stephansson E, Leirisalo-Repo M: Lupus anticoagulant
as a prognostic marker in systemic lupus erythematosus. Br J Rheum 32:568-573,
80. Bulpitt KJ, Clements PJ, Lachenbruch PA, et al: Early undifferentiated
connective tissue disease: III. Outcome and prognostic indicators in early
scleroderma (systemic sclerosis). Ann Intern Med 118:602-609, 1993.
81. Langevitz LP, Alderdice CA, Aubrey M, et al: Morality in systemic
sclerosis (scleroderma). J Med 82(298):139-148, 1992.
82. Altman RD, Medsger TA, Bloch DA, et al: Predictors of survival in
systemic sclerosis (scleroderma). Arthritis Rheum 34(4):403-413, 1991.
83. Drachman DB: Myasthenia gravis. N Engl J Med 330(25):1797-1810,
84. Sanders DB, Scoppetta C: The treatment of patients with myastenia
gravis. Neurol Clin North Am 12(2):343-368, 1994.
85. Somnier FE, Keiding N, Paulson OB: Epidemiology of myastenia gravis
in Denmark. Arch Neurol 48:733-739, 1991.
86. Probert CSJ, Jayanthi V, Wicks ACB, et al: Mortality from Crohn's
disease in Leicestershire, 1972-1989: An epidemiological community based
study. Gut 33:1226-1228, 1992.
87. Mendelsohn RR, Korelitz BI, Gleim GW: Death from Crohn's disease
and lessons from a personal experience. J Clin Gastroenterol 20(1):22-26,
88. Love LA, Leff RL, Fraser DD, et al: A new approach to the classification
of idiopathic inflammatory myopathy: Myositis-specific auto-anitbodies
define useful homogeneous patient groups. Medicine 70:360, 1991.